Close Menu

NEW YORK (GenomeWeb) — Goldman Sachs on Tuesday released an omnibus report of its views on specific companies and sectors of the life sciences industry. The investment bank upgraded shares of Agilent to Buy; Thermo Fisher Scientific to the Americas Conviction Buy List; and Myriad to Neutral. Goldman also downgraded PerkinElmer to Sell and Danaher and Laboratory Corporation of America to Neutral.

The bank also raised its view of the life science tools sector to Attractive, lowered its view of the labs sector to Neutral, and reiterated its Neutral view of the diagnostics market.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Nature News reports that researchers in Japan hope to soon test the use of reprogrammed stem cells to treat damaged corneas.

A new approach may help limit the number of fish that are mislabeled at markets or restaurants, according to New Scientist.

At Slate, the R Street Institute's Nila Bala discusses the privacy rights of suspects that genetic genealogy approaches in law enforcement bring up.

In PNAS this week: numerous mobile genetic elements contribute to Vibrio cholerae drug resistance, troponin I mutations in sudden infant deaths, and more.